Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 18, Issue -, Pages 38-52Publisher
ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12040
Keywords
Antifungal agents; candida disease; children; Europe; neonates
Categories
Funding
- National Institute of Health Research (NIHR)
- Medical Research Council
- National Institute for the Replacement, Refinement and Reduction, of Animals in Research
- Pfizer
- Gilead
- Schering-Plough
- Merck
- Astellas
- Enzon
- Schering
- Astellas Pharma
- Gilead Sciences
- Merck Sharp and Dohme
- MSD
- German Federal Ministry of Research and Education (BMBF) [01KN1106]
- bioMerieux
- Soria Melguizo SA
- Ferrer International
- European Union
- ALBAN program
- Spanish Agency for International Cooperation
- Spanish Ministry of Culture and Education
- Spanish Health Research Fund
- Instituto de Salud Carlos III
- Ramon Areces Foundation
- Mutua Madrilena Foundation
- Bio-Merieux
- Cephalon
- Merck Sharp
- Dohme
- Astra Zeneca
- Novartis
- GSK
- ESCMID
- Abbott
- BMS
- Nadirex Internation (Pavia, Italy)
- Jansen
- MSD (Schering-Plough)
- National Institute for Health Research [CS/08/08/10] Funding Source: researchfish
Ask authors/readers for more resources
Clin Microbiol Infect 2012; 18 (Suppl. 7): 3852 Abstract Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin +/- Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available